Supplemental High Flow Oxygen to Reduce Infections in Obese Gynecological Cancer Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-85
SponsorNational and Kapodistrian University of Athens

About this trial

The incidence of surgical-site infection (SSI) and complications related to wound healing reaches 10-20% of gynecological cancer patients. Each complication may dramatically prolong the hospitalization period and increase the economic burden of hospital care. Appropriate wound care and tissue oxygenation are of special importance for wound healing. Assuming adequate perfusion, the easiest, safest, and most effective way to improve tissue oxygenation is to increase the fraction of inspired oxygen. However, there is considerable controversy as to whether supplemental oxygen actually reduces SSI and healing-related complications as to date, there is absence of relevant data.

Eligibility criteria

Qualifiers

Obese (BMI>30kg/m2) gynecological cancer patients

Optimized preoperative CBC values (hemoglobin >11g/dl, WBC 4.000-11.000 X 109/L, platelets 150,000 to 400,000 X 109/L)

In the case of neoadjuvant therapy an interval longer than three weeks between the last cycle and the operation

Disqualifiers

Active immunosuppresion

Preexisting infection of the abdominal wall

Preexisting sepsis

Trial design

Treatments tested in this trial

  • Supplemental oxygen therapy

Treatment groups

400 Participants
are divided into 2 treatment groups